Engagement of circular RNA HECW2 in the nonautophagic role of ATG5 implicated in the endothelial-mesenchymal transition

Li Yang, Bing Han, Yuan Zhang, Ying Bai, Jie Chao, Gang Hu & Honghong Yao

To cite this article: Li Yang, Bing Han, Yuan Zhang, Ying Bai, Jie Chao, Gang Hu & Honghong Yao (2017): Engagement of circular RNA HECW2 in the nonautophagic role of ATG5 implicated in the endothelial-mesenchymal transition, Autophagy, DOI: 10.1080/15548627.2017.1414755

To link to this article: https://doi.org/10.1080/15548627.2017.1414755
Engagement of circular RNA HECW2 in the nonautophagic role of ATG5 implicated in the endothelial-mesenchymal transition

Running title: Role of circular RNA HECW2 in EndoMT

Li Yang¹, Bing Han¹, Yuan Zhang¹, Ying Bai¹, Jie Chao², Gang Hu³, Honghong Yao¹,⁴,*

¹Department of Pharmacology, School of Medicine, Southeast University, Nanjing, Jiangsu, China; ²Department of Physiology, School of Medicine, Southeast Nanjing, Jiangsu, China; ³Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, China; ⁴Institute of Life Sciences, Key Laboratory of Developmental Genes and Human Disease, University, Nanjing, Jiangsu, China

*Corresponding author: Honghong Yao, Ph.D., Department of Pharmacology, Medical School of Southeast University; E-mail: yaohh@seu.edu.cn
Abstract

Endothelial-mesenchymal transition (EndoMT) is associated with damage to blood-brain barrier (BBB) integrity. Circular RNAs (circRNAs) are highly expressed in the brain and are involved in brain diseases; however, whether circRNAs regulate the EndoMT in the brain remains unknown. Our study demonstrated that circHECW2 regulated the EndoMT by directly binding to MIR30D, a significantly downregulated miRNA from miRNA profiling, which subsequently caused an increased expression of ATG5. These findings shed new light on the understanding of the noncanonical role of ATG5 in the EndoMT induced by methamphetamine (Meth) or lipopolysaccharide (LPS). The in vivo relevance was confirmed as microinjection of circHecw2 siRNA lentivirus into the mouse hippocampus suppressed the EndoMT induced by LPS. These findings provide novel insights regarding the contribution of circHECW2 to the nonautophagic role of ATG5 in the EndoMT process in the context of drug abuse and the broad range of neuroinflammatory disorders.

Keywords
ATG5; circular RNA HECW2; EndoMT; endothelial cell; LPS; methamphetamine; MIR30D; nonautophagy
Introduction

It has been established that the disruption of the blood-brain barrier (BBB) integrity is involved in the context of drug abuse and other brain disorders; however, the mechanisms that underlie the damage of the BBB integrity remain unclear. Under this pathological condition, cerebral microvascular endothelial cells lose their protective function, which leads to BBB damage. Endothelial to mesenchymal transition (EndoMT) is a dynamic process by which endothelial cells (ECs) dedifferentiate into mesenchymal cells and, as a result, lose their specific phenotype and function. Dedifferentiation of endothelial cells to mesenchymal cells has also been identified in brain disorders, particularly multiple sclerosis (MS), thus lending credence to the hypothesis that the EndoMT may contribute to BBB damage. However, few studies have investigated the potential role of the EndoMT in BBB damage during drug abuse and the broad neuroinflammation context.

MicroRNAs (miRNAs) are involved in numerous central nervous system pathologies, including brain tumors, neurodegeneration and MS. Moreover, miRNAs are envisioned as therapeutic strategies to treat neurovascular-dependent brain diseases because a number of miRNAs have been implicated in the regulation of EC function under normal and inflammatory conditions. A previous study demonstrates that Mir31 acts as a positive modulator of the EndoMT in mouse pancreatic microvascular endothelial cells. However, the specific roles of miRNAs in the EndoMT in the brain are largely unknown. Therefore, miRNA profiling was performed to identify the specific miRNA in the cell function regulation of human
brain microvascular endothelial cells (HBMECs) treated with methamphetamine (Meth). \textit{MIR30D} was characterized because its downregulation was validated in HBMECs treated with Meth or lipopolysaccharide (LPS). Thus, we deemed it necessary to identify the downstream target of \textit{MIR30D} and gain further insights regarding whether \textit{MIR30D} plays a role in the EndoMT.

A genome-wide bioinformatic analysis indicated that the circular RNA \textit{HECW2} (\textit{circHECW2}), derived from exon 12 and exon 13 of the \textit{HECW2} gene, acts as a sponge for \textit{MIR30D}. Circular RNAs (circRNAs), generated from back-spliced exons, have recently been identified as a naturally occurring family of noncoding RNAs that are highly represented in the eukaryotic transcriptome.\textsuperscript{15} circRNAs are highly homologous and, in general, more stable than their linear counterparts because they lack accessible ends and are thus resistant to exonucleases.\textsuperscript{16} Several classes of noncoding RNAs are involved in the regulation of physiological and pathophysiological processes, including neural development and plasticity, Alzheimer disease, heart senescence, hypertrophy and failure, and cell growth.\textsuperscript{17-22} However, whether \textit{circHECW2} is involved in the EndoMT remains unknown, and more extensive studies are required.

Therefore, our current study demonstrated that the \textit{circHECW2-MIR30D} axis was involved in the nonautophagic role of ATG5 in the EndoMT process, which provides a potential novel therapeutic strategy for cerebrovascular damage in the context of drug abuse and broad neuroinflammation-related diseases.
Results

MIR30D is downregulated in vitro and in vivo

As miRNAs are signaling factors that affect cerebrovascular permeability by regulating structural components,\textsuperscript{23, 24} we aimed to identify the potential role of specific miRNAs in the cerebrovascular dysfunction induced by Meth using a microRNA array. Variations in the miRNA expression between the controls and samples were shown with a heat map and scatter plot. \textit{MIR30D} was significantly downregulated (up to 53.56-fold) (Fig. 1A and B). The reduction in \textit{MIR30D} was further confirmed via real-time PCR in HBMECs treated with Meth (Fig. 1C). Interestingly, this finding was also validated in HBMECs stimulated with LPS (Fig. 1D). Consistent with this \textit{in vitro} finding, LPS administration in mice significantly decreased \textit{mir30d} expression in the hippocampus (Fig. 1E). A TargetScan algorithm was subsequently applied to predict the target genes of \textit{MIR30D}. As shown in Fig. S1, the \textit{ATG5} (autophagy related 5) gene that has a conserved \textit{MIR30D} binding site within its 3'-\textit{UTR} in most species, was identified as the putative target of \textit{MIR30D}. Intriguingly, cotransfection of a \textit{MIR30D}-overexpressing vector and \textit{pmiR-GLO} plasmid with the \textit{ATG5} WT 3'-\textit{UTR} resulted in the downregulation of luciferase activity, and this effect was reversed in HEK293T cells transfected with a mutated
ATG5 3’-UTR (ATG5 3’-UTRΔ) (Fig. 1F). Consistent with this finding, MIR30D decreased ATG5 expression, whereas anti-MIR30D increased its expression in HBMECs at the protein level (Fig. 1G).

Meth or LPS increases ATG5 expression independent of autophagy

Because ATG5 is the target of MIR30D, we subsequently aimed to explore the effects of Meth or LPS on the autophagy of HBMECs. As shown in Fig. 2A, LPS (10 ng/ml) treatment significantly increased the expression of BECN1/Beclin 1 and ATG5/ATG5; however, the same treatment failed to induce the conversion from cytosolic MAP1LC3B/LC3B-I to membrane-bound MAP1LC3B/LC3B-II (Fig. 2B). Consistent with this unexpected finding, LPS (10 ng/ml) failed to decrease the expression of SQSTM1/p62, a marker protein that functions as a link between MAP1LC3B and the ubiquitinated substrate; instead, treatment increased its expression (Fig. 2B). In addition to LPS treatment, exposure of cells to Meth (100 μM) increased the expression of BECN1 and ATG5 (Fig. S2A), but failed to increase the level of MAP1LC3B-II as well as decrease the expression of SQSTM1 (Fig. S2B). To rule out false-negative findings, HBMECs were exposed to a higher concentration of Meth or LPS for different time points. As shown in Fig. 2C, LPS (100 ng/ml) significantly increased the conversion of MAP1LC3B-II and decreased the expression
of SQSTM1, which was further confirmed in the cells treated with Meth (1 mM) (Fig. S2C).

We then directly investigated the macroautophagic/autophagic flux by visualizing the HBMECs transfected with a tandem fluorescent-mRFP-GFP-MAP1LC3B-adenovirus. The colocalization of GFP and RFP (yellow puncta) indicates the lack of fusion phagophores or autophagosomes with lysosomes, whereas the RFP-only signals (red puncta) indicate the presence of autolysosomes. As shown in Fig. 2D and E, LPS (10 ng/ml) exposure failed to induce an autophagic influx, whereas there are significantly increased yellow dots per cell accompanied by an increase in RFP-only dots after the LPS (100 ng/ml) treatment; we identified similar evidence following Meth treatment (Fig. S2D). Consistent with this finding, treatment with LPS (100 ng/ml) alone caused accumulation of MAP1LC3B-II, and treatment with LPS (100 ng/ml), and NH₄Cl/Leu further enhanced the accumulation of MAP1LC3B-II (Fig. 2F). This finding was further confirmed in HBMECs treated with Meth (1 mM) (Fig. S2E). These findings indicated that the lower concentrations of Meth or LPS increased ATG5 expression without autophagy activation; however, higher concentrations of Meth or LPS increased ATG5 expression and autophagy activation. Consistent with these in vitro findings, the administration of LPS in mice increased ATG5 expression and concomitantly increased SQSTM1 expression without affecting the MAP1LC3B-II level (Fig. 2G).
**ATG5 is involved in the EndoMT**

Following the detection of the surprising phenomenon that ATG5 expression was increased in the HBMECs treated with Meth (100 μM) or LPS (10 ng/ml) without autophagy activation, we aimed to examine the role of ATG5 in endothelial cell dysfunction because Meth or LPS treatment have been determined to cause BBB injury.\(^{26,27}\) As shown in Fig. 3A, the LPS administration significantly decreased the expression of all 3 tight junction proteins (TJPs). The EndoMT is a dynamic process by which ECs dedifferentiate into mesenchymal cells and thus lose their specific phenotype and function; thus, we aimed to examine whether the EndoMT is responsible for EC damage after LPS treatment. As shown in Fig. 3B, LPS administration significantly increased the expression of COL1A2/Collagen I and ACTA2/α-SMA (actin, alpha 2, smooth muscle, aorta), which are markers of mesenchymal cells. To verify this finding, the BBB integrity and EndoMT were further confirmed using a TEK/Tie2-GFP transgenic mouse model combined with a 2-photon analysis. As shown in Fig. 3C, the Dil-labeled monocytes out of blood vessels in the LPS mice were significantly increased compared with those in the saline mice as accessed via 2-photon laser scanning microscopy (TPLSM). In this same set of experiments, the LPS group exhibited a significantly increased colocalization rate, which was 2.21-fold (Pearson correlation) and 3.07-fold (Manders overlap) higher than that in the saline group (Fig. 3D and E).
Consistent with the *in vivo* findings, the exposure of HBMECs to Meth or LPS significantly decreased the expression of TJP with a concomitantly increased expression of mesenchymal cell markers (Fig. S3). To examine the role of ATG5 in the EndoMT, HBMECs were transfected with ATG5 siRNA. As expected, the ATG5 siRNA successfully decreased ATG5 expression (Fig. S4A). Knockdown of ATG5 expression significantly inhibited the decreased expression of TJP induced by Meth or LPS (Fig. S4B and Fig. 3F). Consistently, Meth or LPS treatment displayed increased mesenchymal cell marker expression, which was significantly ameliorated by the ATG5 siRNA transfection (Fig. S4C and Fig. 3G).

*Engagement of the MIR30D-ATG5 axis in the EndoMT*

Following the determination that MIR30D regulates ATG5 expression, we aimed to examine whether MIR30D was involved in the EndoMT induced by Meth or LPS. As shown in Fig. S5A and Fig. 4A, the transduction of cells with MIR30D lentivirus significantly ameliorated the decreases in the TJP expression induced by Meth or LPS. In contrast, the increases in the mesenchymal cell marker expression were significantly inhibited by the transduction of HBMECs with MIR30D lentivirus (Fig. S5B and Fig. 4B). We subsequently aimed to examine whether ATG5 is the functional target of MIR30D. The transduction of HBMECs with anti-MIR30D lentivirus decreased the expression of TJP, and this effect was significantly inhibited in cells.
cotransduced with the lentiviral vectors that expressed \textit{anti-MIR30D} and \textit{ATG5} siRNA (Fig. 4C). Moreover, the transduction of HBMECs with \textit{anti-MIR30D} lentivirus resulted in enhanced mesenchymal cell marker expression, and this effect was inhibited in cells cotransduced with the lentiviral vectors that expressed \textit{anti-MIR30D} and \textit{ATG5} siRNA (Fig. 4D). These results indicate that \textit{ATG5} acts as a functional target of \textit{MIR30D} to regulate the EndoMT.

\textit{circHECW2 functions to bind MIR30D}

After determining the role of the \textit{MIR30D-ATG5} axis in the EndoMT, we subsequently obtained insight into the mechanisms of \textit{MIR30D} regulation. Since circRNAs act as competing endogenous RNA (ceRNA) sponges to interact with miRNAs and influence their activity, we aimed to examine which circRNA binds \textit{MIR30D}. Using a bioinformatic program, RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid), we determined that \textit{circHECW2} contains one \textit{MIR30D} target site (Fig. 5A). Consistent with the prediction, we subsequently assessed whether \textit{circHECW2} is involved in the EndoMT induced by different stimuli via real-time PCR using divergent primers (Fig. 5B). The treatment of HBMECs with Meth or LPS significantly increased the \textit{circHECW2} expression in HBMECs (Fig. 5C and D). This finding was further confirmed in LPS-treated mice as there was an increased expression of \textit{circHecw2} in the hippocampus (Fig. 5E). Furthermore, we applied a biotin-coupled \textit{MIR30D} mimic to determine whether \textit{MIR30D} was able to pull down \textit{circHECW2}. We identified an enrichment of
circheCW2 in the MIR30D-captured fraction compared with that observed following the introduction of mutations that disrupt base paring between circheCW2 and MIR30D (Fig. 5F). In contrast, by applying a biotin-labeled specific probe, MIR30D was pulled down by circheCW2 (Fig. 5G). Furthermore, the double in situ hybridization indicated that there was a colocalization of circheCW2 and MIR30D in HBMECs (Fig. 5H).

**Knockdown of circheCW2 expression inhibits the EndoMT by targeting MIR30D in vitro**

After determining that circheCW2 binds with MIR30D, we subsequently aimed to examine the role of circheCW2 in the EndoMT. As shown in Fig. S6, the knockdown of circheCW2 successfully decreased the expression of circheCW2 in HBMECs. We then examined the effect of circheCW2 on the EndoMT. As shown in Fig. 6A, the transduction of cells with circheCW2 siRNA significantly ameliorated the decreases in the TJP expression induced by LPS. In contrast, the increased mesenchymal cell marker expressions induced by LPS were significantly inhibited by the transduction of HBMECs with circheCW2 siRNA (Fig. 6B). Consistent with this finding, the knockdown of the expression of circheCW2 also inhibited the EndoMT induced by Meth (Fig. S7A and B). To verify whether MIR30D is a mediator of circheCW2, the transduction of HBMECs with anti-MIR30D significantly inhibited the decrease in the ATG5 expression induced by circheCW2 siRNA lentivirus (Fig. S8). Expectedly, the transduction of HBMECs with anti-MIR30D significantly
inhibited the increases in the TJP expression induced by \textit{circHECW2} siRNA lentivirus (Fig. 6C). Moreover, the transduction of HBMECs with \textit{circHECW2} siRNA lentivirus resulted in decreased mesenchymal cell marker expression, and this effect was inhibited in cells cotransduced with the lentiviral vectors that expressed \textit{circHECW2} siRNA and \textit{anti-MIR30D} (Fig. 6D). These results indicate that \textit{circHECW2} acts as an endogenous \textit{MIR30D} sponge to regulate the EndoMT.

\textbf{Knockdown of \textit{circHecw2} expression inhibits the EndoMT in vivo}

After determining that \textit{circHECW2} has an important influence on the EndoMT \textit{in vitro}, we subsequently aimed to examine the \textit{in vivo} relevance of \textit{circHECW2} by microinjecting a \textit{circHecw2} siRNA lentivirus into the hippocampus of C57BL/6J mice as illustrated in Fig. 7A; the distribution of GFP+ lentiviruses was tracked in the hippocampus as expected (Fig. 7B). We then examined the efficacy of \textit{circHecw2-GFP} siRNA lentivirus transfection \textit{in vivo}. As shown in Fig. 7C, \textit{circHecw2} expression was decreased in the \textit{circHecw2} siRNA-microinjected side compared with that in the \textit{circCon} siRNA-microinjected side. \textit{circHecw2} siRNA significantly ameliorated the decreases in the TJP expression induced by LPS (Fig. 7D and E). In contrast, the increased expression of mesenchymal cell markers induced by LPS treatment was significantly inhibited with \textit{circHecw2} siRNA-microinjected (Fig. 7F and G).

\textit{Involvement of the NOTCH1/Notch1 pathway in the \textit{circHECW2-MIR30D-ATG5-mediated EndoMT}}
NOTCH1/Notch1 signaling is involved in the EndoMT in cardiac ECs and kidney fibrosis,\textsuperscript{28-31} thus, we subsequently examined whether this pathway was involved in the EndoMT regulated by the $\text{circHECW2-MIR30D-ATG5}$ axis. As shown in Fig. 8A, LPS treatment significantly increased the NOTCH1/NICD (notch intracellular domain) level. ATG5 siRNA inhibited the enhanced NOTCH1 level induced by anti-$\text{MIR30D}$ (Fig. 8B). We subsequently examined the effect of $\text{circHECW2}$ on the NOTCH1 signaling pathway. As shown in Fig. 8C, the transduction of HBMECs with $\text{circHECW2}$ siRNA lentivirus significantly ameliorated the increased NOTCH1 level induced by LPS. The transduction of HBMECs with $\text{circHECW2}$ siRNA lentivirus resulted in a decreased NOTCH1 level, and this effect was inhibited in cells cotransfected with the lentiviral vectors that expressed $\text{circHECW2}$ siRNA and anti-$\text{MIR30D}$ (Fig. 8D). These results indicate that $\text{circHECW2}$ acts as an endogenous $\text{MIR30D}$ sponge to regulate NOTCH1 signaling.

**Discussion**

Our study provides novel insights into the function of $\text{circHECW2}$, which was shown to be involved in the EndoMT induced by drug abuse and another inflammatory stimulus, LPS by binding with $\text{MIR30D}$ and subsequently targeting $\text{ATG5}$ (Fig. 8E). Another novel finding is the nonautophagic role of ATG5 in the EndoMT that contributes to cerebrovascular damage. Specific blockade of
circHECW2 may be envisioned as a potential therapeutic target for the treatment of BBB damage.

Although miRNAs are envisioned as therapeutic strategies for the treatment of neurovascular-dependent brain diseases, the specific roles of miRNAs in the EndoMT in the brain are largely unknown. In addition to Mir31 involved in the EndoMT, other miRNAs, including MIR21, MIR23, MIR20A and MIR302C are also involved in the EndoMT in peripheral cells, such as cardiac endothelial cells and hepatocellular carcinoma cells. The rationale for our selection of MIR30D was as follows: 1) MIR30D screened from a miRNA array was significantly decreased in the Meth-treated group compared with that in the control group; 2) the decreased expression of MIR30D was validated in HBMECs treated with Meth, which was also expanded in LPS-treated HBMECs. MIR30D plays a critical role in tumor cell proliferation and motility, cardiomyocyte apoptosis and the epithelial-mesenchymal transition; however, whether MIR30D is involved in the regulation of the EndoMT has remained largely unknown. To the best of our knowledge, this study is the first investigation to demonstrate that MIR30D is involved in the EndoMT in drug abuse and LPS-induced neuroinflammation. In this study, MIR30D was initially identified using a bioinformatic approach; definitive proof of whether MIR30D is beneficial and its detailed mechanisms may be determined only with gain- or loss-of-function experiments in animal models with Meth or LPS injection in future studies.
Consistent with the TargetScan prediction and a previous study, our current study further confirmed that ATG5 was the target of MIR30D. ATG5, an essential component for canonical autophagy, plays nonautophagic roles in innate antiviral immune responses, T cell survival and proliferation. In this study, to our surprise, treatment with Meth (100 μM) or LPS (10 ng/ml) enhanced the ATG5 level but did not increase the level of autophagy as accessed via MAP1LC3B-II and SQSTM1 immunoblotting. Therefore, the function of ATG5 in this context remains questionable. Whether ATG5 is involved in the BBB integrity also remains elusive.

To the best of our knowledge, this study is the first demonstration that ATG5, as the target of MIR30D, functions in the EndoMT induced by Meth or LPS, which lends credence to our speculation that MIR30D and ATG5 contributed to the EndoMT during BBB damage. To rule out false-negative findings, we also performed additional experiments with higher concentrations of Meth (1 mM) or LPS (100 ng/ml) as these treatments induced the activation of autophagy in HBMECs. These results indicated that in contrast to the lower concentrations of Meth or LPS, canonical autophagy was induced by the higher concentrations. Our findings are consistent with a previous study which indicates that for reprogramming of induced pluripotent stem cells (iPSCs), different reprogramming induction strengths with different concentrations of doxycycline determine the reprogramming pathway in ATG5-dependent canonical autophagy. Our study also shares features with the noncanonical role of ATG5 proposed in a previous study in which the upregulation of
ATG5 mediated by DNA-damaging agents promotes mitotic catastrophe independent of autophagy. The detailed mechanisms of the noncanonical role of ATG5 remain largely unknown, and specific tools are lacking; thus, it is technically challenging to thoroughly characterize the noncanonical role of ATG5 in the EndoMT.

Although the functions of circRNAs are largely unknown, accumulating evidence suggests that they are key regulators of numerous biological functions in neural development and plasticity, as well as Alzheimer disease; however, whether they are involved in the pathogenesis of drug abuse or in the broad neuroinflammation context has not currently been determined. Consistent with the findings of previous studies, the current study indicated that circHECW2 acts as a MIR30D sponge to regulate the EndoMT and downregulates the expression of circHecw2, attenuating cerebrovascular damage in mice treated with LPS. The interaction between MIR30D and circHECW2 was confirmed by miRNA affinity isolation and double fluorescence in situ hybridization (FISH) assays. In addition to acting as sponges to interact with miRNAs, circRNAs exert their functions via another mechanism as illustrated in a recent study which indicates that circFox3 regulates cell cycle progression by conjugating with CDKN1A/p21 and CDK2. Although MIR30D is regulated by circHECW2, we could not rule out the other mechanisms that contribute to the functions of circHECW2.
circRNAs have been identified to play a specific role in the epithelial-mesenchymal transition;\textsuperscript{48} however, none of these studies have investigated the role of circRNAs in the EndoMT. Increasing evidence indicates the role of the EndoMT in cardiac development and various pathological conditions;\textsuperscript{49-52} however, most studies regarding the EndoMT have been performed in embryonic development or nonbrain-derived endothelial cells. To the best of our knowledge, this study is the first investigation to demonstrate that the EndoMT contributed to cerebrovascular damage in drug abuse or a broader neuroinflammation induced by LPS. Moreover, a TEK-GFP genetic mouse model was applied for a colocalization analysis as the mesenchymal cell marker ACTA2 colocalized with TEK-GFP. The molecular mechanisms involved in the switch from an endothelial phenotype to a mesenchymal status are complicated and controlled by various signaling pathways, such as the WNT, NOTCH and TGFB pathways.\textsuperscript{53-55} Consistent with a previous study,\textsuperscript{54} NOTCH1 signaling lies downstream of \textit{circHECW2-MIR30D-ATG5} as shown in our current study. Given that ATG5 contains substantial numbers of acidic residues, a potential glycosylation site, protein kinase C and tyrosine kinase sites,\textsuperscript{56} further investigation was required to identify the precise mechanism that underlies the activation of the NOTCH1 pathway induced by \textit{circHECW2-MIR30D-ATG5}.

In summary, \textit{circHECW2} was involved in the EndoMT that results in the damage of BBB integrity via the suppression of MIR30D activity as an endogenous MIR30D sponge and subsequent downstream activation of ATG5. The \textit{circHECW2-MIR30D}
axis thus lies upstream of the nonautophagic role of ATG5 in the EndoMT. Specific
blockage of circHECW2 may be envisioned as a potential therapeutic target for the
treatment of BBB integrity damage.

Materials and Methods

Reagents

The lentiviral vectors that carried MIR30D overexpression, anti-MIR30D,
circHECW2 siRNA and an adenoviral vector that carried mRFP-GFP-MAP1LC3B
(HB-AP2100001) were obtained from HANBIO (Shanghai, China). The control
siRNA (sc-37007) and human ATG5 siRNA (sc-41445) were acquired from Santa
Cruz Biotechnology. Leupeptin (L2884), NH₄Cl (A9434) and LPS (L2630) were
obtained from Sigma-Aldrich. Methamphetamine was purchased from the National
Institute for the Control of Pharmaceutical and Biological Products (Lot,
171212-201104; ID, 26CYK7B6).

Animals

C57BL/6J mice (male, 5 to 6 weeks) and STOCK TEK-GFP 287Sato/JNju mice were
obtained from the Laboratory Animal Center of Nanjing Medical University (Nanjing,
China); the GFP expresses only in endothelial cells. All animals were housed at a
constant temperature and humidity with a 12 h light: 12 h dark cycle, with lights on at
08:00 am. Food and water were available ad libitum. The animals were deeply
anesthetized with Nembutal, followed by perfusion. All animal procedures were
conducted according to the protocols approved by the Institutional Animal Care and Use Committee of the Medical School, Southeast University.

**Cell cultures**

Primary human brain microvascular endothelial cells (HBMECs) were purchased from ScienCell, cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies, 22400089) and used at passages 4 to 14. The culture was incubated to confluence in T25 flasks in a humid atmosphere at 37°C with 5% CO₂. The cultured cells were negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast, and fungi.

**MicroRNA microarray assay**

The microarray assay was performed by a service provider (LC-Bio, Hangzhou, China) as follow. HBMECs were treated with Meth at a concentration of 100 μM. After 6 h, RNA was extracted and pooled from triplicate samples in each control and Meth-treated group. The assay was performed with 4 to 5 μg of the total RNA samples, which were 3’-extended with a poly (A) tail using a poly (A) polymerase (NEB, M0276L). An oligonucleotide tag was subsequently ligated to the poly (A) tail for fluorescent dye staining. The hybridization was performed overnight on a μParaflo microfluidic chip using a microcirculation pump (Atactic Technologies, Houston, USA). The detection probes were created via in situ synthesis using photogenerated reagent chemistry. After the RNA hybridization, a tag-conjugating Cy3 dye was
circulated through the microfluidic chip for the dye staining. Fluorescence images were collected using a laser scanner (GenePix 4000B, Molecular Device, USA) and digitized using Array-Pro image analysis software (Media Cybernetics). The data were initially analyzed by subtracting the background and then normalizing the signals using a LOWESS filter (locally weighted regression).

The Gene Expression Omnibus (GEO) accession code for the data in this manuscript is GSE96063.

**Western blot (WB) analysis**

According to our previous studies,$^{57,58}$ proteins were extracted in a RIPA lysis buffer (Beyotime, P0013B). The proteins were separated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. After blocking with 5% nonfat dry milk in Tris-buffered saline (20 mM Tris-HCl, 500 mM NaCl, pH7.4) with 0.2% Tween-20 (Aladdin, T104863), the membranes were probed with antibodies overnight at 4°C, followed by incubation with a horseradish peroxidase-conjugated goat anti-mouse (ZSGB-BIO, ZB5305) or goat anti-rabbit (ZSGB-BIO, ZB5301) IgG secondary antibody (1:2000). The antibodies were as follows: anti-ATG5 (sc33210) obtained from Santa Cruz Biotechnology; anti-GAPDH (60004), anti-SQSTM1 (18420), anti-MAP1LC3B/LC3B (14600), anti-NOTCH1 (10062), anti-BECN1 (11306), anti-TJP1 (21773) and anti-ACTA2 (14395) were obtained from Proteintech; anti-COL1A2 (BS1530) was obtained from Bioworld Technology; anti-CLDN5
(AF0130) was obtained from Affinity; and anti-ACTB (3700) and anti-OCLN (5506) were obtained from Cell Signaling Technology. The detection was performed using a MicroChemi 4.2® (DNR, Jerusalem, Israel) digital image scanner. The band intensity was quantified using ImageJ software (NIH).

**Real-time PCR**

According to our previous studies, total RNA was extracted and subjected to reverse transcription using a HiScript RT SuperMix Kit (Vazyme, R133-01 for miRNAs, R123-01 for mRNAs). Real-time PCR was performed by StepOne™ Real-Time PCR System (Life Technologies, 4376357, Singapore) using the following primers: human circHECW2 (forward primer: 5′-GGCTGTCAATGCGTGCCT-3′), human GAPDH (forward primer: 5′-ACCATCTTCCAGGAGCGAGAT-3′; reverse primer: 5′-GGGCAGAGATGATGACCCTTT-3′), mouse circHecw2 (forward primer: 5′-AACAGGGACCTCGTGGGATT-3′; reverse primer: 5′-GGCTGTCAATCCGTGCCTC-3′) and mouse Gapdh (forward primer: 5′-AGGTCGGTGAACGGATTGTTG-3′; reverse primer: 5′-GGGTCCTTGATGGCAACA-3′). The relative quantification was performed using AceQ qPCR SYBR Green Master Mix (Vazyme, Q141-02). The specific primers for the mature MIR30D and RNU6-6P/RNU6B snRNA were purchased from RiboBio. All reactions were performed in triplicate.
Luciferase activity assays

The 3′-UTR of the 706-base pair human ATG5 gene that contained the putative MIR30D target site was PCR amplified from human genomic DNA using forward (5′-GCGGCTCGAGGAAAATGGAAGTATGTGCC-3′) and reverse (5′-ATATCGGCGCCGCACTTCAAAGACTGGCTGC-3′) primers; the DNA fragment was cloned into the XhoI and NotI sites on the 3′ end of the luc2 gene in a pmiR-RB-GLO vector (RiboBio, GUR100000). For the pmiR-RB-ATG5-3′-UTR∆-MIR30D-target-mutant vector, the MIR30D target site (TGTTTACA) within the ATG5 3′-UTR was changed to ACAAAATGT via PCR mutagenesis with the primers ATG5-MIR30DT-F (5′-ATTTCTAACAATGTGTCTGTCTTATGGTATGC-3′) and ATG5-MIR30DT-R (5′-AGACAGACACATTTTGTAGGAAATTTCGTTAAG-3′).

Briefly, HEK293T cells were transfected with a MIR30D overexpression pLV-[Hsa-MIR30D] vector (RiboBio) and a target plasmid, pmiR-RB-Bbc3-3′-UTR or pmiR-RB-ATG5-3′-UTR∆-MIR30D-target-mutant (RiboBio), at a molar ratio of 50:1. A MIRCon pLV-[MIRCon] vector was used as a negative control. The luciferase activity was determined at 24 h post-transfection, and a reporter assay was performed following the manufacturer’s protocol (Promega, E2920). The Renilla luciferase activity was normalized to the firefly luciferase activity and expressed as a percentage of the control.

Affinity isolation assay with biotinylated MIR30D

22
A total of 2x10^6 HEK293T cells were seeded the day before the transfection, and the cells were transfected with 3'-end biotinylated MIR30D at a final concentration of 50 nM for 36 h. The cells were subsequently washed with phosphate-buffered saline (PBS; 2.96mM Na_2HPO_4·7H_2O, 1.05mM KH_2PO_4, 155.17mM NaCl, pH 7.4) and incubated in a lysis buffer (20 mM Tris, pH 7.5, 200 mM NaCl, 2.5 mM MgCl_2, 0.05% Igepal [Sigma-Aldrich, I3021], 60 U/ml SUPERase-In [Ambion, AM2694], 1 mM DTT [Sigma-Aldrich, 43816], and protease inhibitors [Biotool, B14001] on ice for 10 min. After being precleared, 50-μl aliquots of the samples were used as the input. The remaining lysates were incubated in M-280 Streptavidin magnetic beads (Life Technologies, 11205D), which were previously coated with yeast tRNA (Invitrogen, 15401011) to prevent the nonspecific binding of the RNA and protein complexes. The beads were incubated at 4°C for 2.5 h, followed by being washed twice with ice-cold lysis buffer, twice with a low-salt buffer (0.1% SDS [Invitrogen, 15553035], 1% Triton X-100 [Aladdin, T109027], 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl), and once with a high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl). The bound RNAs were isolated using Trizol (TaKaRa, 9109) to measure the circHECW2 level. The 3'-end biotinylated MIR30D was synthesized by GenePharma (Shanghai, China), and its sequence was 5'-UGUAAACAUCCCCGACUGGAUU-3'.

**Affinity isolation assay with the biotinylated DNA probe**
The biotinylated DNA probes, complementary to circHECW2, were dissolved in 500 ml of the wash/binding buffer (0.5 M NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM EDTA). The probes were incubated in M-280 Streptavidin magnetic beads at 4°C for 3 h to generate probe-coated magnetic beads. The HEK293T cell lysates were incubated with the probe-coated beads at 25°C for 1.5 h, and the RNA complexes bound to the beads were eluted and extracted for real-time PCR analysis after being washed with the wash/binding buffer. The following primer sequence was used: circHECW2 affinity-isolation probe (Invitrogen),

5'-aaaATGAGTGCCCTCCCAGTCTTGCCCTGGTGATCA-3'; and random

affinity-isolation probe (Invitrogen),

5'-aaaCAGTACTGGTGTGTAGTACGAGTCTAAGCTAC-3'.

**Microinjection of circHecw2 siRNA lentivirus**

Six-week-old C57BL/6J mice were bilaterally microinjected with control-GFP or circHecw2-GFP siRNA lentivirus (1 μl of 10^9 viral genomes μl^-1, HANBIO) in the hippocampus using the following microinjection coordinates: 2.06 mm posterior to bregma, ±1.5 mm lateral from the sagittal midline, and 1.7 mm ventral to the skull surface. To evaluate the effect of circHECW2 on the LPS-induced EndoMT, twelve mice were divided into the following 2 groups (n=6 animals/group, male) 2 weeks after lentivirus microinjection: the saline-treated mouse group and the LPS-treated mouse group. The rationale for the selection of this dosage of LPS (0.83 mg/kg, injected once per day for 7 d, intraperitoneal) was based on previous studies.6, 61
Immunostaining and image analysis

According to our previous studies,\textsuperscript{58,59} the sections that encompassed the entire hippocampus were cut into 30-\(\mu\)m slices with a cryostat. The sections were subsequently incubated with 0.3% Triton X-100 in PBS for 15 min and blocked with 10% normal goat serum (ZSGB-BIO, ZLI-0956) in 0.3% Triton X-100 for 1 h at room temperature. Next, the sections were incubated with a rabbit anti-ACTA2 antibody overnight at 4°C. On the following day, the sections were washed and incubated with Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen, A-11037) for 1 h. After a final washing step with PBS, the sections were mounted onto glass slides. The immunofluorescence images were captured via microscopy (Carl Zeiss LSM700, Zeiss, Oberkhorn, Germany). The intensities of ACTA2 and GFP were calculated using PSC colocalization and Manders coefficients.\textsuperscript{62}

Tandem fluorescent-mRFP-GFP-MAP1LC3B-adenovirus transduction of HBMECs

According to our previous study,\textsuperscript{59} HBMECs were transfected with a fluorescent-mRFP-GFP-MAP1LC3B-adenovirus that expresses a specific marker of autophagosome formation to detect autophagy according to the manufacturer’s instructions. Five fields were selected from 3 different cell preparations. GFP- and mRFP-expressing spots, which were indicated by fluorescent puncta, and 4’,6-diamidino-2-phenylindole (DAPI, SouthernBiotech, 010020) -stained nuclei were
manually counted. The number of puncta per cell was determined by dividing the total number of spots by the number of nuclei in each field.

**Bone marrow-derived monocyte (BMM) isolation and Dil staining**

Cultured BMMs were 98% ITGAM+/CD11b+ as demonstrated via flow cytometry in our previous study; to evaluate the monocyte migration, monocytes were washed with PBS and fluorescently labeled with 10 μM Dil (Beyotime, C1036) for 10 min at room temperature according to the manufacturer’s instructions.

**In vivo 2-photon laser scanning microscopy (TPLSM) for monocyte migration**

According to our previous and other studies, for the monocyte migration studies, animals were injected with Dil-labeled BMM at a concentration at 10⁷ cells/100 μl through the tail vein and subsequently subjected to TPLSM to detect the monocyte migration 24 h after the cell infusion. Cortical brain vessels 20 to 40 μm in diameter and 100 to 150 μm in depth below the cortical surface were selected for the 2-photon imaging. Z-stack images of 50-μm-thick tissue sections were collected at 2-μm steps, and 3-dimensional pictures were constructed using ZEN2011 Imaging Software (Zeiss) to calculate the number of monocytes that migrated to the parenchyma.

**Fluorescence in situ hybridization (FISH)**

According to our previous study, HBMECs cultured in a coverslip were fixed with 4% paraformaldehyde for 20 min and incubated in PBS overnight at 4°C. The cells were permeabilized with 0.25% Triton X-100 in PBS for 15 min and prehybridized in
a hybridization buffer (50% formamide, 10 mM Tris-HCl [pH 8.0], 200 μg ml⁻¹ yeast tRNA, 1X Denhardt's solution [Sigma-Aldrich, 30915], 600 mM NaCl, 0.25% SDS, 1 mM EDTA and 10% dextran sulfate [Sigma-Aldrich, D8906]) for 1 h at 37°C. The hybridization buffer, which contained 25 nM of a commercially available digoxigenin-labeled \textit{MIR30D} probe (synthesized by Invitrogen) and 50 nM of a commercially available biotin-labeled \textit{circHECW2} probe (synthesized by Invitrogen), was subsequently heated to 65°C for 5 min; the hybridization was allowed to occur at 37°C overnight. On the following day, the coverslips were washed 3 times with 2XSSC (10% v/v 20X SSC [Invitrogen, 15557] in DEPC-treated water [Vetec, V90082]) and twice with 0.2X SSC at 42°C and then blocked with 1.5% BSA (Biosharp, BS043D) and 3% normal goat serum in PBS for 1 h at room temperature. The coverslips were subsequently incubated with a horseradish peroxidase-conjugated anti-digoxigenin antibody (1:200; Roche Diagnostics GmbH, 11207733910) and FITC-Streptavidin (1:200; Life Technologies, 434311) overnight at 4°C. After the coverslips were washed 3 times with TBS, they were incubated using a TSA Cy5 kit (PerkinElmer, NEL766B001KT) for 10 min at room temperature. The coverslips were subsequently washed twice with PBS and mounted with ProLong Gold anti-fade reagent, which contained Hoechst (Life Technologies, H3570). The digoxigenin-labeled \textit{MIR30D} probe was CTTCCAGTCGGGGATGTTTACA (Invitrogen); biotin-labeled \textit{circHECW2} probe was 5’-aaaATGAGTGCCCTCCCAGTCTTGCCCTGGTGATCA-3’ (Invitrogen).
Statistical analyses

Statistical analyses were performed using the Mann-Whitney test or one-way analysis of variance (ANOVA) followed by the Holm-Sidak test (SPSS 16.0). The appropriate test is indicated in the figure legends. Results were judged statistically significant when $P<0.05$ via analysis of variance.

Abbreviations

ACTA2: actin, alpha 2, smooth muscle, aorta

ACTB: actin beta

ATG5: autophagy related 5

BBB: blood-brain barrier

BECN1: beclin 1

circRNA: circular RNA

circHECW2: circular HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2

CLDN5: claudin 5

COL1A2: collagen type I alpha 2 chain

EC: endothelial cell

EndoMT: endothelial-mesenchymal transition

FISH: fluorescence in situ hybridization
GAPDH: glyceraldehyde-3-phosphate dehydrogenase

HBMECs: human brain microvascular endothelial cells

LPS: lipopolysaccharide

MAP1LC3B: microtubule associated protein 1 light chain 3 beta

Meth: methamphetamine

MIR30D: microRNA30d-5p

miRs: microRNAs

OCLN: occludin

PCR: polymerase chain reaction

SQSTM1: sequestosome 1

TJP: tight junction protein

TJP1: tight junction protein 1

UTR: untranslated region

WT: wild type
Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 81473190, No. 81673410 and No. 81603090) and grants from the Jiangsu Specially Appointed Professor and the Major State Basic Research Development Program of China (973 Program) (2013CB733800 and 2013CB733803).

Conflict of Interest Disclosures

The authors declare that there are no competing financial interests.
References


Guidelines for the use and interpretation of assays for monitoring autophagy. 


44. Maskey D, Yousefi S, Schmid I, Zlobec I, Perren A, Friis R, Simon HU. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe


et al. MiR-9 promotes microglial activation by targeting MCPIP1. Nature
communications. 2014; 5:4386. doi:10.1038/ncomms5386.

KW, Dantzer R. Lipopolysaccharide-induced depressive-like behavior is
mediated by indoleamine 2,3-dioxygenase activation in mice. Molecular

62. French AP, Mills S, Swarup R, Bennett MJ, Pridmore TP. Colocalization of
fluorescent markers in confocal microscope images of plant cells. Nature

TP, Wang JQ, Buch S. Molecular mechanisms involving sigma
receptor-mediated induction of MCP-1: implication for increased monocyte
doi:10.1182/blood-2010-01-266221.

64. Wang H, Hong LJ, Huang JY, Jiang Q, Tao RR, Tan C, Lu NN, Wang CK,

Figure legends

**Figure 1.** *MIR30D* is downregulated *in vitro* and *in vivo*. (A) Heat map indicates the differential expressions of microRNAs in HBMECs between control and Meth-treated groups. *MIR30D* expression is downregulated in HBMECs. Down- and upregulated genes are indicated by green and red, respectively. (B) Scatter plot represents the visualization method used to assess variations in microRNA expression between control and Meth-treated groups. The values for the X and Y axes represent
normalized signal values (log10 scale). 6 h after the treatment of HBMECs with Meth (100 μM), RNA was extracted and pooled from triplicate samples in each control and Meth-treated group. (C and D) Effect of Meth or LPS on MIR30D expression in HBMECs. HBMECs were treated with Meth (100 μM) or LPS (10 ng/ml) for 6 h, followed by RNA extraction. All data are presented as the mean±SD of 4 independent experiments. *P<0.05 versus vehicle control using the Mann-Whitney test. (E) Effect of LPS on Mir30D expression in the hippocampus of mice. Mice were treated with saline or LPS (0.83 mg/kg) once per day for 7 d. n=6 animals/group. **P<0.01 versus saline group using the Mann-Whitney test. (F) Relative luciferase activity of wild-type and 3'-UTRΔ mutant constructs of ATG5 cotransfected with a MIR30D overexpression vector and pmiR-GLO plasmid. All data are presented as the mean±SD of 3 individual experiments. *P<0.05 versus the MIRCon cotransfected with the WT construct via one-way ANOVA followed by the Holm-Sidak test. (G) MIR30D regulated the expression of ATG5 in HBMECs. Representative western blots indicate the ATG5 expression in HBMECs exposed to MIR30D or anti-MIR30D lentivirus. All data are presented as the mean±SD of 5 independent experiments. **P<0.01 versus MIRCon group or anti-MIRCon group using the Mann-Whitney test.

HBMECs: human brain microvascular endothelial cells; Meth: methamphetamine.
Figure 2. Effects of different concentrations of LPS on the expression of autophagy-associated proteins. (A and B) Effects of LPS (10 ng/ml) on the expression of BECN1 and ATG5 (A), MAP1LC3B-II and SQSTM1 (B). Cells were treated with LPS (10 ng/ml) for different time points. (C) Effects of LPS (100 ng/ml) on the expression of MAP1LC3B-II and SQSTM1. Cells were treated with LPS (100 ng/ml) for different time points. All data are presented as the mean±SD of 4
independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus vehicle control using one-way ANOVA. (D and E) Effects of LPS on RFP- and GFP-MAP1LC3B puncta. HBMECs transduced with the RFP-GFP-MAP1LC3B adenovirus and subsequently treated with different concentrations of LPS for 24 h. The RFP- and GFP-MAP1LC3B puncta per cell were counted, and the quantification is shown in (E). Scale bar: 5 μm. Quantification of cell numbers is presented as the mean±SD of 3 independent experiments. ***P<0.001 versus vehicle control. ###P<0.001 versus the LPS (10 ng/ml)-treated group using one-way ANOVA followed by the Holm-Sidak test. (F) Effect of LPS on the MAP1LC3B-II expression. HBMECs were treated with LPS (100 ng/ml) for 24 h. A lysosomal inhibitor mix (NH₄Cl [20 mM], Leu [200 μM]) was added 1 h prior to cell harvesting, and the cell lysate was collected and analyzed via immunoblotting for MAP1LC3B-II accumulation. ***P<0.001 versus vehicle control. ###P<0.001 versus the LPS (100 ng/ml)-treated group using one-way ANOVA followed by the Holm-Sidak test. (G) Expression of ATG5, MAP1LC3B-II and SQSTM1 in the hippocampus isolated from mice treated with LPS. C57BL/6J mice were treated with LPS (0.83 mg/kg) or saline once per day for 7 d followed by determination of the expression of autophagic proteins. n=6 animals/group. *P<0.05, **P<0.01 versus saline group using the Mann-Whitney test. Leu, leupeptin.
Figure 3. Role of ATG5 in LPS-induced EndoMT. (A and B) Effects of LPS treatment on the expression of TJP (TJP1, OCLN and CLDN5) (A) and mesenchymal cell markers (COL1A2 and ACTA2) (B) in vivo. (C) The number of Dil-labeled monocytes increased out of the blood vessels of LPS-treated TEK-GFP transgenic mice compared with that in the saline treatment. Mice were treated with LPS (0.83
mg/kg) once per day for 7 d and were subsequently accessed via TPLSM. Scale bar: 50 μm. (D and E) Effect of LPS on the GFP+ and ACTA2 colocalization in vivo. Immunostaining for ACTA2 in the hippocampus from TEK-GFP transgenic mice. Z-tack images were acquired on a Carl Zeiss confocal laser scanning microscope (D). The Pearson correlation or Manders overlap of the GFP+ and ACTA2 immunofluorescence was calculated, respectively (E). Scale bar: 5 μm. Mice were administered LPS (0.83 mg/kg) once per day for 7 d. n=6 animals/group. *P<0.05, **P<0.01, ***P<0.001 versus saline group using the Mann-Whitney test. (F and G) Transfection of HBMECs with siRNA ATG5 significantly inhibited the decreases in the TJP expression levels (F) and the increases in the mesenchymal cell marker expression (G). HBMECs were cultured for 24 h after the transfection of ATG5 siRNA and were subsequently exposed to LPS (10 ng/ml) for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus the siRNA-control group. #P<0.05, ##P<0.01 versus the LPS-incubated siRNA-control via one-way ANOVA followed by the Holm-Sidak test.
Figure 4. The MIR30D-ATG5 axis plays an important role in the EndoMT. (A and B)

Transduction of HBMECs with MIR30D lentivirus significantly inhibited the LPS-induced decreases in the TJP expression levels (A) and increases in the mesenchymal cell marker expression (B). HBMECs were transduced with the MIR30D lentivirus for 24 h and were subsequently incubated with LPS (10 ng/ml) for
24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus the MIRCon group. #P<0.05, ##P<0.01, ###P<0.001 versus the LPS-treated MIRCon group via one-way ANOVA followed by the Holm-Sidak test. (C and D) Transduction of HBMECs with the ATG5 siRNA significantly inhibited the decreases in the TJP expression levels (C) and the increases in the mesenchymal cell marker expression (D) induced by anti-MIR30D. HBMECs were cotransduced with anti-MIRCon or anti-MIR30D and either control siRNA or ATG5 siRNA for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01 versus the anti-MIRCon group with the control siRNA. #P<0.05, ##P<0.01 versus the anti-MIR30D cotransduced with the control siRNA via one-way ANOVA followed by the Holm-Sidak test.
Figure 5. circHECW2 sponges MIR30D. (A) circHECW2 contained one site complementary to MIR30D. The potential complementary residues are presented in red, as determined using the bioinformatic program RNAhybrid. (B) Divergent primers amplified circHECW2 in cDNA but not genomic DNA (gDNA). GAPDH, linear control. (C and D) Effects of Meth or LPS on circHECW2 expression in HBMECs. Real-time PCR was performed to measure the circHECW2 expression levels in HBMECs treated with Meth (100 μM) (C) or LPS (10 ng/ml) (D) for 6 h. All
data are presented as the mean±SD of 4 independent experiments. *P<0.05 versus vehicle control using the Mann-Whitney test. (E) Effect of LPS on circHecw2 expression in the hippocampus of mice. Mice were administered LPS (0.83 mg/kg) once per day for 7 d. n=6 animals/group. **P<0.01 versus saline group using the Mann-Whitney test. (F) Application of a biotin-coupled MIR30D mimic to determine whether MIR30D was able to pull down circHECW2. The biotinylated wild-type MIR30D (Bio-MIR30D-WT) or its biotinylated mutant (Bio-MIR30DΔ) was transfected into HEK293T cells. After streptavidin capture, the circHECW2 and GAPDH mRNA levels were quantified via real-time PCR, and the relative immunoprecipitate/input ratios were plotted. All data are presented as the mean±SD of 3 independent experiments. **P<0.01 versus the Bio-MIR30D-WT group via one-way ANOVA followed by the Holm-Sidak test. (G) Following the application of a biotin-labeled specific probe, MIR30D was pulled down by circHECW2. The biotinylated circHECW2 (Bio-circHECW2) or circRNA negative control (Bio-Random) was transfected into HEK293T cells. After streptavidin capture, the MIR30D and RNU6-6P microRNA levels were quantified via real-time PCR, and the relative immunoprecipitate/input ratios were plotted. All data are presented as the mean±SD of 4 independent experiments. **P<0.01 versus the Bio-Random group via one-way ANOVA followed by the Holm-Sidak test. (H) Double-label in situ hybridization assays showed that circHECW2 colocalized with MIR30D. Scale bar: 10 μm. bp, base pair; M, size markers; Meth, methamphetamine.
Figure 6. Knockdown of circHECW2 expression inhibits the EndoMT by targeting MIR30D in vitro. (A and B) Transduction of HBMECs with circHECW2 siRNA lentivirus significantly inhibited the LPS-induced decreases in the TJP expression levels (A) and the increases in the mesenchymal cell marker expression (B).
HBMECs were transduced with the circHECW2 lentivirus for 24 h and were subsequently incubated with LPS (10 ng/ml) for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01 versus the circCon siRNA group. #P<0.05, ##P<0.01, ###P<0.001 versus the LPS-treated circCon siRNA via one-way ANOVA followed by the Holm-Sidak test. (C and D) Transduction of HBMECs with the anti-MIR30D lentivirus significantly inhibited the increases in the TJP expression levels (C) and the decreases in the mesenchymal cell marker expression (D) induced by circHECW2 siRNA. HBMECs were cotransduced with anti-MIR30D and circHECW2 siRNA for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus the circCon siRNA cotransduced with the anti-MIRCon group. #P<0.05, ###P<0.001 versus the circHECW2 siRNA cotransduced with the anti-MIRCon group via a one-way ANOVA followed by the Holm-Sidak test.
Figure 7. Knockdown of circHecw2 inhibits the EndoMT in vivo. (A) Schematic diagram presents the procedure for microinjection of circHecw2 siRNA lentivirus prior to LPS treatment in mice. (B) Representative images of C57BL/6J mice bilaterally microinjected with siRNA-GFP lentivirus (1 μl of 10⁹ viral genomes μl⁻¹) in the hippocampus. Scale bar: 200 μm. (C) circHecw2 siRNA lentivirus injection successfully decreased circHecw2 expression. Two weeks after the microinjection, mice were sacrificed and assessed regarding the circHecw2 level as determined via real-time PCR. n=6 animals/group. *P<0.05 versus circCon using the Mann-Whitney
test. (D to G) Microinjection of C57BL/6J mice with circHev2 siRNA lentivirus significantly inhibited the LPS-induced decreases in the TJP expression levels (D and E) and the increases in the mesenchymal cell marker expression (F and G). Mice were microinjected with the circHev2 siRNA or circCon siRNA lentivirus for 2 weeks and were subsequently treated with LPS (0.83 mg/kg) once per day for 7 d. n=6 animals/group. *P<0.05, **P<0.01, ***P<0.001 versus the saline-treated circCon siRNA group. #P<0.05, ##P<0.01, ###P<0.001 versus the LPS-treated circCon siRNA group via one-way ANOVA followed by the Holm-Sidak test.
**Figure 8.** Involvement of the NOTCH1 pathway in the 
circHECW2-MIR30D-ATG5-mediated EndoMT. (A) LPS induced an increased 
cleavage of NOTCH1/NICD from NOTCH1. Cells were treated with LPS (10 ng/ml) 
for different time points. All data are presented as the mean±SD of 3 independent 
experiments. *P<0.05, **P<0.01, ***P<0.001 versus the vehicle control via one-way 
ANOVA. (B) Transduction of HBMECs with ATG5 siRNA significantly inhibited the 
increases in the NOTCH1 level induced by anti-MIR30D lentivirus. HBMECs were 
cotransduced with anti-MIR30D and ATG5 siRNA for 24 h. All data are presented as 
the mean±SD of 3 independent experiments. ***P<0.001 versus the anti-MIRCon 
cotransduced with the control siRNA group. **P<0.01 versus the anti-MIR30D 
cotransduced with the ATG5 siRNA via one-way ANOVA followed by the 
Holm-Sidak test. (C) Transduction of HBMECs with circHECW2 siRNA lentivirus 
significantly inhibited the level of NOTCH1 induced by LPS. HBMECs were 
transduced with the circHECW2 siRNA or circCon siRNA for 24 h and were 
subsequently incubated with LPS (10 ng/ml). All data are presented as the mean±SD 
of 3 independent experiments. *P<0.05, **P<0.01 versus the circCon siRNA group 
via one-way ANOVA. #P<0.05 versus the LPS-treated circCon siRNA group via 
one-way ANOVA followed by the Holm-Sidak test. (D) Transduction of HBMECs 
with the anti-MIR30D lentivirus significantly inhibited the decreases in the NOTCH1 
level induced by circHECW2 siRNA. HBMECs were cotransduced with anti-MIR30D 
and circHECW2 siRNA. All data are presented as the mean±SD of 3 independent
experiments. **$P<0.01$ versus the circCon siRNA with anti-MIRCon-cotransduced group. *$P<0.05$ versus the circHECW2 siRNA with anti-MIRCon-cotransduced group via one-way ANOVA followed by the Holm-Sidak test. (E) circHECW2, identified as ceRNA, functioned as an endogenous MIR30D sponge to sequester MIR30D and inhibited its activity, which resulted in increased ATG5 expression and consequent EndoMT via the NOTCH1 signaling pathway.
**Supplementary Figure 1**

**Figure S1.** *MIR30D* targets *ATG5*. *ATG5* has a conserved *MIR30D* binding site within its 3'-UTR in most species, using a TargetScan algorithm. The potential complementary residues are shown in red.
Supplementary Figure 2

Figure S2. Effects of different concentrations of Meth on the expression of autophagy-associated proteins. (A and B) Effects of Meth (100 μM) on the expression of BECN1 and ATG5 (A) MAP1LC3B-II and SQSTM1 (B). Cells were treated with Meth (100 μM) for different time points. (C) Effects of Meth (1 mM) on the expression of MAP1LC3B-II and SQSTM1. Cells were treated with Meth (1 mM) for different time points. All data are presented as the mean±SD of 4 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus vehicle control using one-way ANOVA followed by the Holm-Sidak test. (D) Effects of Meth on RFP- and GFP-MAP1LC3B puncta. HBMECs were transduced with the RFP-GFP-MAP1LC3B adenovirus and then treated with different concentrations of Meth for 24 h. The RFP-
and GFP-MAP1LC3B puncta per cell were counted. Scale bar: 5 μm. Quantification of cell numbers is presented as the mean±SD of 3 independent experiments. **P<0.01, ***P<0.001 versus vehicle control. ###P<0.001 versus the Meth (100 μM)-treated group using a one-way ANOVA followed by the Holm-Sidak test. 

(E) Effect of Meth on MAP1LC3B-II expression. HBMECs were treated with Meth (1 mM) for 24 h. A lysosomal inhibitor mix (NH₄Cl [20 mM], Leu [200 μM]) was treated 1 h prior to cell harvest, and cell lysate was collected and analyzed by immunoblotting for MAP1LC3B-II accumulation. ***P<0.001 versus vehicle control. ##P<0.01 versus the Meth (1 mM)-treated group using a one-way ANOVA followed by the Holm-Sidak test. Leu, leupeptin; Meth, methamphetamine.
**Figure S3**: Effect of Meth or LPS on the EndoMT in HBMECs. (A and B) Effect of Meth on the expression of TJP and mesenchymal cell markers. Cells were treated with Meth (100 μM) for different time points. (C and D) Effect of LPS on the expression of the TJP and mesenchymal cell markers. Cells were treated with LPS (10 ng/ml) for different time points. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus vehicle control using a one-way ANOVA. Meth, methamphetamine.
Supplementary Figure 4

Figure S4. ATG5 is involved in Meth-induced EndoMT. (A) Knockdown of ATG5 decreased the expression level of ATG5. HBMECs were transfected with ATG5 siRNA for 24 h followed by determination for the expression of ATG5. (B and C) Transfection of HBMECs with ATG5 siRNA significantly inhibited the decreases in the TJP expression levels (B) and the increases in the mesenchymal cell marker expression (C). HBMECs were transfected with ATG5 siRNA and then exposed to Meth (100 μM) for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus the siRNA-control group. #P<0.05, ##P<0.01 versus the Meth-treated siRNA-control group in one-way ANOVA followed by the Holm-Sidak test. Meth, methamphetamine.
Supplementary Figure 5

Figure S5. Transduction of HBMECs with MIR30D inhibits the Meth-induced EndoMT. (A and B) Transduction of HBMECs with MIR30D lentivirus significantly inhibited the Meth-induced decreases in the TJP expression levels (A) and increases in the mesenchymal cell marker expression (B). HBMECs were transduced with the MIR30D lentivirus for 24 h and then exposed to Meth (100 μM) for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, **P<0.01, ***P<0.001 versus the MIRCon group. #P<0.05, ##P<0.01, ###P<0.001 versus the Meth-treated MIRCon group in one-way ANOVA followed by the Holm-Sidak test. Meth, methamphetamine.
Supplementary Figure 6

Figure S6. Knockdown of circHECW2 decreases the expression of circHECW2. HBMECs were transduced with the circHECW2 siRNA or circCon siRNA lentivirus for 24 h followed by analysis for the level of circHECW2 using real-time PCR. The data are shown as the mean±SD of 4 independent experiments. *P<0.05 versus control siRNA group using a Mann-Whitney test.
Supplementary Figure 7

**Figure S7.** Knockdown of circHECW2 inhibits the Meth-induced EndoMT. (A and B) Transduction of HBMECs with circHECW2 siRNA lentivirus significantly inhibited the Meth-induced decreases in the TJP expression (A) and the increases in the mesenchymal cell marker expression (B). HBMECs were transduced with the circHECW2 siRNA lentivirus for 24 h and then exposed to Meth (100 μM) for 24 h. All data are presented as the mean±SD of 3 independent experiments. **P<0.01, ***P<0.001 versus the circCon siRNA group. ##P<0.01, ###P<0.001 versus the Meth-treated circCon siRNA group in one-way ANOVA followed by the Holm-Sidak test. Meth, methamphetamine.
Supplementary Figure 8

**Figure S8.** Transduction of HBMECs with the ant-MIR30D lentivirus significantly inhibited the decrease in ATG5 expression induced by circHECW2 siRNA. HBMECs were cotransduced with ant-MIR30D and circHECW2 siRNA for 24 h. All data are presented as the mean±SD of 3 independent experiments. *P<0.05, ***P<0.001 versus the circCon siRNA group. ##P<0.01 versus the circHECW2 siRNA cotransduced with ant-MIRCon group in one-way ANOVA followed by the Holm-Sidak test.